AI Stock Analysis - Anavex Life Sciences (AVXL)
Analysis generated April 17, 2026.
Anavex Life Sciences is a biopharmaceutical company focused on the development of novel drugs for the treatment of neurodegenerative and neurodevelopmental diseases, including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, and other central nervous system (CNS) diseases. They utilize precision medicine and advanced developments in genomics for their drug discovery and development processes.
Stock Alerts - Anavex Life Sciences (AVXL)
 |
Anavex Life Sciences | April 14 Price is up by 6.1% in the last 24h. |
|
Anavex Life Sciences | March 31 Price is up by 6.7% in the last 24h. |
|
Anavex Life Sciences | March 26 Price is up by 7.7% in the last 24h. |
|
Anavex Life Sciences | March 25 Price is down by -28.4% in the last 24h. |
Download our app on iOS or Android to get future alerts delivered in real-time.
Alternative Data for Anavex Life Sciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 91 | Sign up | Sign up | Sign up |
| Webpage traffic | 9,000 | Sign up | Sign up | Sign up |
| Employee Rating | N/A | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 72 | Sign up | Sign up | Sign up |
| Facebook Followers | 1,633 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 275 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 24,275 | Sign up | Sign up | Sign up |
| X Followers | 2,176 | Sign up | Sign up | Sign up |
| X Mentions | 25 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | N/A | Sign up | Sign up | Sign up |
| Business Outlook | N/A | Sign up | Sign up | Sign up |
About Anavex Life Sciences
Anavex utilizes precision genetic medicine to treat severe and devastating neurological disorders and is focusing on rare diseases with no available therapy (Rett syndrome) as well as neurodegenerative diseases that are on the rise due to aging populations (Parkinson's Disease and Alzheimer's Disease) More about us.
| Price | $3.40 |
| Target Price | Sign up |
| Volume | 993,762 |
| Market Cap | $315M |
| Year Range | $2.74 - $11.35 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s DiseaseApril 14 - GlobeNewswire |
|
Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare ConferenceApril 7 - GlobeNewswire |
|
Anavex Life Sciences Provides Comprehensive Regulatory UpdateMarch 30 - GlobeNewswire |
|
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s DiseaseMarch 25 - GlobeNewswire |
|
Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s DiseaseMarch 23 - GlobeNewswire |
|
Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 ConferenceMarch 17 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '25 | 0 | 0 | 0 | -5.7M | 0 | -0.060 |
| Q3 '25 | 0 | 0 | 0 | -9.8M | -9.8M | -0.110 |
| Q2 '25 | 0 | 0 | 0 | -13M | -13M | -0.160 |
| Q1 '25 | 0 | 0 | 0 | -11M | 1.1M | -0.132 |
| Q4 '24 | 0 | 0 | 0 | -12M | -11M | -0.140 |
Insider Transactions View All
| Donhauser Peter D.O. filed to buy 5,000 shares at $3.6. June 17 '24 |
| Thomas Steffen filed to buy 5,000 shares at $4.5. May 17 '24 |
| MISSLING CHRISTOPHER U filed to sell 1,250,210 shares at $5.1. April 1 '24 |
| MISSLING CHRISTOPHER U filed to sell 1,018,210 shares at $8. June 30 '23 |
| Skarpelos Athanasios filed to sell 1,306,458 shares at $9.1. May 27 '22 |
Similar companies
Read more about Anavex Life Sciences (AVXL) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews & business outlook.
FAQ - Anavex Life Sciences
The Market Cap of Anavex Life Sciences is $315M.
Currently, the price of one share of Anavex Life Sciences stock is $3.40.
The AVXL stock price chart above provides a comprehensive visual representation of Anavex Life Sciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Anavex Life Sciences shares. Our platform offers an up-to-date AVXL stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Anavex Life Sciences (AVXL) does not offer dividends to its shareholders. Investors interested in Anavex Life Sciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Anavex Life Sciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and BridgeBio Pharma.
